AI Engines For more Details: Perplexity Kagi Labs You
Local Anesthesia: Dibucaine belongs to the class of medications known as local anesthetics, which work by blocking nerve signals in a specific area of the body, leading to temporary loss of sensation or pain relief. Dibucaine is used to provide local anesthesia for minor surgical procedures, dental procedures, and medical interventions involving the skin, mucous membranes, or other superficial tissues.
Topical Application: Dibucaine is most commonly administered topically as a cream, ointment, gel, or solution that is applied directly to the skin or mucous membranes to numb the area before a procedure or to relieve pain or itching associated with minor skin conditions such as insect bites, minor burns, cuts, abrasions, or hemorrhoids.
Analgesic Effects: Dibucaine provides temporary pain relief by blocking the transmission of pain signals from sensory nerves to the brain. It can help alleviate discomfort and pain associated with minor injuries, skin irritations, or medical procedures, allowing patients to undergo treatment or perform activities with greater comfort.
Anti-Itch Properties: In addition to its analgesic effects, dibucaine has mild anti-itch properties that can help relieve itching and irritation associated with insect bites, allergic reactions, dermatitis, or other inflammatory skin conditions. Dibucaine may be used alone or in combination with other medications to provide relief from itching and discomfort.
Onset and Duration of Action: Dibucaine typically has a rapid onset of action, with numbing effects occurring within minutes after application to the skin or mucous membranes. The duration of action varies depending on factors such as the concentration of dibucaine, the site of application, and individual patient factors, but generally lasts for several hours before wearing off.
Side Effects: While generally safe when used as directed, dibucaine can cause local side effects such as skin irritation, redness, swelling, or allergic reactions in some individuals. Prolonged or excessive use of dibucaine or application to large areas of the body may increase the risk of systemic side effects such as systemic toxicity or allergic dermatitis.
Contraindications: Dibucaine is contraindicated in individuals with a known hypersensitivity or allergy to the medication or any of its components. It should not be applied to broken or inflamed skin, mucous membranes, or areas with impaired barrier function, as this may increase the risk of systemic absorption and adverse effects.
Interactions: Dibucaine may interact with other medications or substances, including other local anesthetics, that affect the nervous system or cardiovascular function. It's important for individuals using dibucaine to inform their healthcare provider about all other medications, supplements, or topical products they are using to avoid potential interactions or adverse effects.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
ADHD | 1.4 | 1.4 | |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
Allergic Rhinitis (Hay Fever) | 1.3 | 0.4 | 2.25 |
Allergies | 2 | 0.6 | 2.33 |
Allergy to milk products | 0.7 | 1.3 | -0.86 |
Alopecia (Hair Loss) | 1.1 | 1.1 | |
Alzheimer's disease | 2.4 | 2 | 0.2 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 0.4 | 1 |
Ankylosing spondylitis | 1.9 | 0.6 | 2.17 |
Anorexia Nervosa | 0.4 | 1.1 | -1.75 |
Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
Asthma | 1.8 | 0.8 | 1.25 |
Atherosclerosis | 2.2 | 0.8 | 1.75 |
Atrial fibrillation | 1 | 1.6 | -0.6 |
Autism | 2.7 | 4.5 | -0.67 |
Autoimmune Disease | 0.6 | 0.5 | 0.2 |
Barrett esophagus cancer | 0.3 | 0.3 | |
benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
Biofilm | 1 | 1 | |
Bipolar Disorder | 1.6 | 0.5 | 2.2 |
Brain Trauma | 0.5 | 0.8 | -0.6 |
Breast Cancer | 0.5 | 0.5 | |
Cancer (General) | 0.3 | 0 | 0 |
Carcinoma | 2 | 0.7 | 1.86 |
Celiac Disease | 1.4 | 1 | 0.4 |
Cerebral Palsy | 0.3 | 0.8 | -1.67 |
Chronic Fatigue Syndrome | 1.1 | 1.8 | -0.64 |
Chronic Kidney Disease | 1.3 | 0.8 | 0.63 |
Chronic Lyme | 0.8 | -0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.8 | -0.14 |
Chronic Urticaria (Hives) | 1 | 0.3 | 2.33 |
Coagulation / Micro clot triggering bacteria | 1.4 | 0.5 | 1.8 |
Cognitive Function | 0.7 | 0.5 | 0.4 |
Colorectal Cancer | 3.4 | 1.5 | 1.27 |
Constipation | 1.1 | 0.5 | 1.2 |
Coronary artery disease | 1 | 1.1 | -0.1 |
COVID-19 | 2.9 | 1.5 | 0.93 |
Crohn's Disease | 4.7 | 1.8 | 1.61 |
Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
cystic fibrosis | 1 | 0.8 | 0.25 |
d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
deep vein thrombosis | 1.8 | 0.8 | 1.25 |
Denture Wearers Oral Shifts | 0.1 | 0.1 | |
Depression | 4.1 | 2.7 | 0.52 |
Eczema | 0.9 | 0.3 | 2 |
Endometriosis | 1.7 | 0.9 | 0.89 |
Eosinophilic Esophagitis | 0.3 | 0.3 | |
Epilepsy | 1.8 | 1.3 | 0.38 |
erectile dysfunction | 1.2 | 1.2 | |
Fibromyalgia | 1.6 | 0.4 | 3 |
Functional constipation / chronic idiopathic constipation | 2.5 | 1.5 | 0.67 |
gallstone disease (gsd) | 2.2 | 0.8 | 1.75 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.9 | |
Generalized anxiety disorder | 1.6 | 0.3 | 4.33 |
Gout | 0.3 | 0.3 | |
Graves' disease | 0.7 | 0.8 | -0.14 |
Gulf War Syndrome | 0.3 | -0.3 | |
Halitosis | 0.7 | 0.7 | |
Hashimoto's thyroiditis | 1.4 | 0.6 | 1.33 |
Heart Failure | 1.8 | 0.5 | 2.6 |
hemorrhagic stroke | 0.7 | 0.7 | |
Hidradenitis Suppurativa | 1.4 | 1.4 | |
High Histamine/low DAO | 2.2 | 2.2 | |
hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
hyperglycemia | 1 | 0.7 | 0.43 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.9 | 1.4 | 0.36 |
Hypothyroidism | 0.5 | 0.5 | |
Hypoxia | 1.7 | 1.7 | |
IgA nephropathy (IgAN) | 1 | 0.7 | 0.43 |
Inflammatory Bowel Disease | 3.1 | 2.7 | 0.15 |
Insomnia | 0.3 | 0.8 | -1.67 |
Intelligence | 0.8 | 0.8 | |
Intracranial aneurysms | 1 | 1 | |
Irritable Bowel Syndrome | 2.7 | 1.6 | 0.69 |
ischemic stroke | 1.1 | 1.4 | -0.27 |
Liver Cirrhosis | 3.1 | 1.8 | 0.72 |
Long COVID | 2.4 | 1.8 | 0.33 |
Low bone mineral density | 0.5 | -0.5 | |
Lung Cancer | 0.9 | 0.9 | |
Lymphoma | 0.6 | 0.6 | |
Mast Cell Issues / mastitis | 0.7 | 0.7 | |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0.9 | -0.9 | |
Menopause | 0.5 | -0.5 | |
Metabolic Syndrome | 3.1 | 2.5 | 0.24 |
Mood Disorders | 3.4 | 2.5 | 0.36 |
Multiple Sclerosis | 2.4 | 2.1 | 0.14 |
myasthenia gravis | 0.6 | 0.5 | 0.2 |
neuropathic pain | 1.3 | -1.3 | |
Neuropathy (all types) | 1.6 | -1.6 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 1.3 | 0.62 |
NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
Obesity | 3.3 | 2 | 0.65 |
obsessive-compulsive disorder | 2.3 | 0.3 | 6.67 |
Osteoarthritis | 1 | 0.3 | 2.33 |
Osteoporosis | 1.4 | 0.3 | 3.67 |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 3.8 | 2.5 | 0.52 |
Polycystic ovary syndrome | 3.8 | 1.1 | 2.45 |
Premenstrual dysphoric disorder | 0.4 | -0.4 | |
primary biliary cholangitis | 0.4 | -0.4 | |
Primary sclerosing cholangitis | 1.5 | 1 | 0.5 |
Psoriasis | 0.6 | 1.9 | -2.17 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.3 | 1.4 | 1.36 |
Rosacea | 0.5 | -0.5 | |
Schizophrenia | 1.4 | 1.3 | 0.08 |
scoliosis | 0.9 | 0.3 | 2 |
sensorineural hearing loss | 0.5 | 0.5 | |
Sjögren syndrome | 1 | 0.8 | 0.25 |
Sleep Apnea | 0.3 | 0.8 | -1.67 |
Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
Stress / posttraumatic stress disorder | 1.9 | 1.3 | 0.46 |
Systemic Lupus Erythematosus | 2.1 | 0.8 | 1.63 |
Tic Disorder | 0.3 | 0.3 | |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 1.7 | 1.1 | 0.55 |
Type 2 Diabetes | 3.6 | 2.6 | 0.38 |
Ulcerative colitis | 2.9 | 2.2 | 0.32 |
Unhealthy Ageing | 1.5 | 1 | 0.5 |
Vitiligo | 1 | 0.4 | 1.5 |